Marshall Wace LLP Acquires 111,119 Shares of Insulet Co. (NASDAQ:PODD)

Marshall Wace LLP lifted its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 29.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 486,516 shares of the medical instruments supplier's stock after purchasing an additional 111,119 shares during the quarter. Marshall Wace LLP owned 0.69% of Insulet worth $127,015,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Baillie Gifford & Co. increased its holdings in Insulet by 3.5% in the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock valued at $614,998,000 after buying an additional 79,982 shares during the period. Geode Capital Management LLC increased its holdings in Insulet by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier's stock worth $463,347,000 after purchasing an additional 40,566 shares in the last quarter. Norges Bank bought a new stake in Insulet during the 4th quarter worth about $248,806,000. Artisan Partners Limited Partnership increased its stake in shares of Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after purchasing an additional 149,524 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Insulet by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier's stock worth $168,902,000 after buying an additional 10,694 shares during the period.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PODD. Citigroup raised their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. Stifel Nicolaus increased their price objective on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday, February 21st. Canaccord Genuity Group increased their target price on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Wells Fargo & Company increased their target price on Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Finally, TD Cowen boosted their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, January 3rd. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and an average target price of $292.06.

Insider Activity at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company's stock, valued at $888,525. This represents a 36.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Insulet Stock Performance

PODD stock traded down $6.49 during mid-day trading on Monday, hitting $240.31. The company had a trading volume of 90,456 shares, compared to its average volume of 714,732. The firm has a market cap of $16.88 billion, a PE ratio of 41.50, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock's fifty day moving average price is $263.29 and its two-hundred day moving average price is $261.21.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. On average, analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.